MREO vs. PRAX, PROK, COLL, AKBA, AMPH, RCUS, DYN, SYRE, VERV, and AVXL
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Spyre Therapeutics (SYRE), Verve Therapeutics (VERV), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs. Its Competitors
Praxis Precision Medicines (NASDAQ:PRAX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Mereo BioPharma Group has higher revenue and earnings than Praxis Precision Medicines. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Mereo BioPharma Group has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -2,137.48%. Praxis Precision Medicines' return on equity of -50.42% beat Mereo BioPharma Group's return on equity.
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Praxis Precision Medicines presently has a consensus target price of $94.11, indicating a potential upside of 68.60%. Mereo BioPharma Group has a consensus target price of $7.20, indicating a potential upside of 292.37%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Praxis Precision Medicines.
In the previous week, Praxis Precision Medicines had 6 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 2 mentions for Mereo BioPharma Group. Praxis Precision Medicines' average media sentiment score of 0.80 beat Mereo BioPharma Group's score of -0.25 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Praxis Precision Medicines has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Summary
Praxis Precision Medicines beats Mereo BioPharma Group on 9 of the 17 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 7/18/2025 by MarketBeat.com Staff
